Investigate atypical presentations of STEMI and the unique challenges they pose in clinical management. This session covers case studies including high bleeding risk patients, mechanical complications post-surgery, spontaneous coronary artery dissection, and recurrent events, emphasizing tailored therapeutic approaches.

Explore novel techniques and emerging technologies in transcatheter tricuspid valve replacement (TTVR). This session showcases innovative devices and approaches, early clinical experiences, and strategies to address challenges such as pacemaker leads and failed tricuspid TEER procedures.

This session delves into the complexities of mitral valve interventions, focusing on valve-in-valve, valve-in-ring, and valve-in-mitral annular calcification (MAC) procedures. It addresses troubleshooting in high-risk valve-in-MAC cases, urgent transcatheter mitral valve implantation supported by microaxial flow pumps, challenges in delivering balloon expandable valves transeptally, and innovative...

This session focuses on the critical evaluation and management of cardiogenic shock by identifying its underlying causes and tailoring treatment accordingly. It presents complex cases including free wall rupture bail-out strategies, management dilemmas in inferior STEMI complicated by incomplete ventricular rupture, multifactorial culprit lesions, refractory hypotension...

Thanks to the contribution of a team of interventional cardiologists from around the globe, get the international perspective on Late-breaking Clinical Trials and Science released at TCT 2024 - check out the list below.

Femoral artery pseudoaneurysm is a known complication following cardiac catheterization. Rarely, expansion of the pseudoaneurysm can occur and is often catastrophic. We describe a unique method employed by our centre to deal with such a complication.

Yohei Ohno provides his takeaways from the results of the Evolut Low Risk trial which was presented by Michael J. Reardon during the ACC.25 in Chicago.

Transcatheter aortic valve implantation (TAVI) offers an effective, less invasive therapeutic alternative to surgical aortic valve replacement in patients with symptomatic, severe aortic stenosis. Although TAVI is demonstrated to be superior to medical therapy or surgery in patients who are at prohibitive or high risk for...

Jonathan Curio provides his take on the PROTECTED TAVR study which was presented by Samir R. Kapadia at TCT 2022. The aim was to evaluate whether TAVR with cerebral embolic protection would reduce the rate of clinical stroke in transfemoral TAVR.

Luigi Biasco provides his take on the clinical trial presented by John K. Forrest from Yale University School of Medicine, New Haven, Connecticut, USA during the 2023 ACC/WCC annual congress held in New Orleans, Louisiana.